Critical Comparison: ARS Pharmaceuticals (SPRY) versus Its Competitors

ARS Pharmaceuticals (NASDAQ:SPRY) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare ARS Pharmaceuticals to similar businesses based on the strength of its risk, analyst recommendations, valuation, earnings, dividends, institutional ownership and profitability.

Profitability

This table compares ARS Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-163.64%	-453.93%	-71.62%
ARS Pharmaceuticals Competitors	-2,393.19%	-220.45%	-16.12%

Institutional and Insider Ownership

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

ARS Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals’ rivals have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for ARS Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1	1	4	0	2.50
ARS Pharmaceuticals Competitors	7820	13783	25790	1036	2.41

ARS Pharmaceuticals presently has a consensus target price of $23.33, suggesting a potential upside of 512.42%. As a group, “Pharmaceuticals” companies have a potential upside of 24.82%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe ARS Pharmaceuticals is more favorable than its rivals.

Valuation and Earnings

This table compares ARS Pharmaceuticals and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28 million	-$171.30 million	-1.89
ARS Pharmaceuticals Competitors	$3.54 billion	$3.17 billion	553.74

ARS Pharmaceuticals’ rivals have higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

ARS Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing needle-free treatments for severe allergic reactions. Its lead product, neffy (epinephrine nasal spray), is designed to provide an alternative to injectable epinephrine for emergency treatment of allergic reactions, including anaphylaxis. The U.S. Food and Drug Administration approved neffy in 2024. The product delivers epinephrine through the nose, addressing the need for a treatment that may be easier to carry and use than an auto-injector.